Try a new search

Format these results:

Searched for:

person:brauej01

in-biosketch:true

Total Results:

68


ABSENCE OF INCREASED RISK OF NEURODEVELOPMENTAL DISORDERS IN CHILDREN UNDERGOING MULTIPLE LASER TREATMENTS OF VASCULAR ANOMALIES UNDER GENERAL ANESTHESIA [Meeting Abstract]

Terushkin, Vitaly; Brauer, Jeremy; Bernstein, Leonard; Geronemus, Roy
ISI:000333055800069
ISSN: 0196-8092
CID: 953232

THE PHOTODYNAMIC THERAPY EXPERIENCE OF A HIGH VOLUME LASER AND DERMATOLOGIC SURGERY CENTER [Meeting Abstract]

Bloom, Bradley; Orbuch, David; Greenbaum, Joshua; Brauer, Jeremy; Bernstein, Leonard; Hale, Elizabeth; Karen, Julie; Brightman, Lori; Weiss, Elliot; Anolik, Robert; Geronemus, Roy
ISI:000333055800123
ISSN: 0196-8092
CID: 953252

Laser therapy in the treatment of connective tissue diseases: a review

Brauer, Jeremy A; Gordon Spratt, Elizabeth A; Geronemus, Roy G
BACKGROUND: Connective tissue diseases (CTD), including lupus erythematosus (LE), scleroderma, sarcoidosis, and dermatomyositis, present with clinically unique cutaneous manifestations often resistant to conventional therapy. The use of lasers in the treatment of various dermatologic conditions continues to expand, presenting an opportunity for incorporation of another mechanism of action in the treatment of CTD. OBJECTIVES: To review the use of laser therapy in the treatment of LE, scleroderma, sarcoidosis, and dermatomyositis. MATERIALS AND METHODS: A MEDLINE search was conducted to find articles detailing treatment of CTD with laser therapy. RESULTS: Thirty-nine published articles were identified. The outcomes and results of case reports were reviewed for each CTD when possible. CONCLUSIONS: Laser therapy offers novel and often effective treatment for recalcitrant cutaneous conditions in LE, scleroderma, sarcoidosis, and dermatomyositis. Review of the literature revealed a limited number of reports, many describing outdated technologies and techniques. It is therefore difficult to draw substantial conclusions regarding safety and the known association with photosensitivity. More-recent reports suggest that, with continued evolution of technology and understanding of CTD, lasers will have an expanding role in the treatment of cutaneous manifestations of CTD.
PMID: 24164782
ISSN: 1076-0512
CID: 906982

Rapid resolution of post-face lift ecchymoses

Brauer, Jeremy A; Geronemus, Roy G
PMID: 24281629
ISSN: 1529-4242
CID: 666252

Skin disease in individuals with liver and kidney transplants: influence of skin phototype and transplanted organ [Letter]

Vuong, Charlotte H; Brauer, Jeremy A; Hochman, Tsivia; Teperman, Lewis; Osman, Iman; Stein, Jennifer A
PMID: 23895208
ISSN: 1076-0512
CID: 573682

Single-Treatment Resolution of Vascular Blebs Within Port Wine Stains Using a Novel 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser [Letter]

Brauer, Jeremy A; Geronemus, Roy G
PMID: 23560945
ISSN: 1076-0512
CID: 409882

Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser

Reddy, Kavitha K; Blei, Francine; Brauer, Jeremy A; Waner, Milton; Anolik, Robert; Bernstein, Leonard; Brightman, Lori; Hale, Elizabeth; Karen, Julie; Weiss, Elliot; Geronemus, Roy G
BACKGROUND: Infantile hemangioma (IH) clearance may be slow or incomplete in response to pulsed dye laser (PDL) or propranolol alone. OBJECTIVES: To evaluate whether IH treated with PDL and propranolol displayed more rapid and complete clearance than IH treated with propranolol alone. MATERIALS AND METHODS: Retrospective review of facial-segmental IH treated with propranolol and PDL and controls treated with propranolol was conducted. Blinded physicians used patient photographs to select clearance level and the earliest date of near-complete clearance. Days of propranolol, PDL sessions, and propranolol dose, each until date of near-complete clearance; total days of propranolol; and total propranolol dose were recorded. RESULTS: Infantile hemangiomas treated concurrently with propranolol and PDL achieved complete clearance (6/12) more often than IH treated with propranolol followed by PDL (2/5) or IH treated with propranolol alone (1/8; difference in clearance scores p = .01) and achieved near-complete clearance after fewer days of propranolol (mean 92 days for concurrent propranolol and PDL vs 288 days for propranolol; p < .001). Cumulative propranolol dose until near-complete clearance was lowest in the concurrent propranolol and PDL group (149.16 vs 401.25 mg/kg for propranolol; p < .001). CONCLUSION: Facial-segmental IH treated with propranolol and PDL displayed morerapid and complete clearance and required a lower cumulative propranolol dose to achieve near-complete clearance.
PMID: 23458381
ISSN: 1076-0512
CID: 409902

Ablative fractional resurfacing in topical drug delivery: an update and outlook

Bloom, Bradley S; Brauer, Jeremy A; Geronemus, Roy G
BACKGROUND: The effective delivery of therapeutic molecules to varied targets in the skin and elsewhere has been an area of ongoing research and development. OBJECTIVE: To review the structure of the skin with an emphasis on topical drug delivery and to present the rationale for the use of ablative and nonablative fractional resurfacing in assisted drug delivery. METHODS AND MATERIALS: Review of the currently available scientific literature on laser-assisted drug delivery. RESULTS: A number of strategies can be employed to enhance topical drug delivery. Ablative fractional resurfacing (AFR) has been demonstrated to be effective in enhancing drug delivery. Further studies are needed to assess the use of nonablative fractional resurfacing in assisted drug delivery. CONCLUSION: AFR-assisted drug delivery is a promising tool for the future of dermatology. We expect to see a number of agents to be paired with AFR for enhanced drug delivery. Further investigation is necessary to evaluate appropriate drug specific channel density and depth parameters. Factors that must be considered include the physicochemical properties of the drug, the target tissue, skin wounding, and cost when evaluating the drugs and conditions that will most benefit from this promising new drug delivery system.
PMID: 23294061
ISSN: 1076-0512
CID: 409922

Surgical corner:a poliglecaprone 25-only approach to wound closure:cosmetic and financial advantages

Lewin, Jesse M; Ostad, Ariel; Brauer, Jeremy A
The primary concerns when performing surgical excisions include adequate control of surgical margins and cosmetic outcome. The ideal repair combines perfect wound approximation, tensile strength, and minimal scarring. Various techniques and suture materials are utilized by dermatologic surgeons to achieve this goal. We describe a Monocryl-only bilayered repair, which can lead to excellent cosmetic results and may reduce the burden of return visits for patients. In this paper, we describe the technique used to place deep Monocryl sutures, as well as a running subcuticular suture, and illustrate this technique with photographs.
PMID: 23545919
ISSN: 1545-9616
CID: 346442

Laser treatment in the management of infantile hemangiomas and capillary vascular malformations

Brauer, Jeremy A; Geronemus, Roy G
Vascular lesions encountered in dermatology can be divided into vascular malformations and vascular tumors, namely infantile hemangiomas (IH). Vascular malformations can further be subdivided by their flow characteristics and vessel type. Slow, or low-flow lesions are either capillary vascular malformations (CVMs), venous malformations, or lymphatic malformations. Fast, or high-flow lesions include an arterial component, and are categorized as arteriovenous malformations. IH and CVMs are among the most common benign vascular lesions seen and treated in dermatology. CVMs are present at birth and grow as the individual does, whereas IH usually appear days to weeks later and may rapidly enlarge for a period of months to a year before gradually involuting. As the technology has evolved, early and often laser treatment with the pulsed dye 595-nm laser has become our standard therapy of choice. More recently, we have started more patients on combination therapy for IH with the topical beta blocker timolol. If left untreated, CVMs darken and thicken, making them increasingly difficult to successfully treat with lasers. IH involute, sometimes resulting in fibrofatty, atrophic plaques. These individuals can undergo ablative fractional resurfacing with a fractional CO2 laser to improve the texture and appearance of these lesions.
PMID: 23499132
ISSN: 1557-9808
CID: 409892